REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS - Andrey Vladislavovich Pavlysh (IRBIS LLC, 2015)